Making diagrams saves time, reduces ambiguity, and leaves a memorable impression on examiners. Check tips shared by the ...

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...

NEW YORK, Jan. 29, 2026 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such investors are advised to ...

Knowable Magazine reports 2025 faced turmoil in U.S. science amid job cuts and budget slashes, yet saw advances in gene ...

Inflammation can feel like a small storm inside your body. It brings heat, swelling, and pain as the immune system rushes to ...

At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 ...

Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...

We recently published 10 Stocks Breaking Records While Wall Street Bleeds. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Tuesday. ImmunityBio saw its share prices rally for a 12 th ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA ...